Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of allogenic or syngenic major histocompatibility complex (MHC) molecules as universal adjuvants for vaccines against neoplastic disease, infection and autoimmune disease

Use of allogenic or syngenic major histocompatibility complex (MHC) molecules as universal adjuvants for vaccines against neoplastic disease, infection and autoimmune disease

US Patent 9155789 · Granted Oct 13, 2015

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Pharmaceutical compositions comprising attenuated Plasmodium sporozoites and gly2017
Modification of recombinant adenovirus with immunogenic plasmodium circumsporozo2017
Pharmaceutical compositions comprising attenuated Plasmodium sporozoites and gly2016
C—glycolipids with enhanced Th-1 profile2014
Glycolipids and analogues thereof as antigens for NKT cells2013
Synthetic C-glycolipid and its use for treating cancer, infectious diseases, and2012
Glycolipids and analogues thereof as antigens for NKT cells2012
Glycolipids and analogues thereof as antigens for NKT cells2011
Use of synthetic glycolipids as universal adjuvants for vaccines against cancer 2010
Glycolipids and analogues thereof as antigens for NK T cells2009
Use of glycosylceramides as adjuvants for vaccines against infections and cancer2009
Synthetic C-glycolipid and its use for treating cancer, infectious diseases and 2007